CSRT.L Regulatory News (CSRT)

Registered Number 406711

Consort Medical plc

Director Declaration

In accordance with Rule 9.6.11 (3) of the UK Listing Rules, Consort Medical plc ('the Company') gives notice that the Board has reviewed the membership of its Remuneration Committee and approved the changes below with effect from 25 April 2018.

Charlotta Ginman and Ian Nicholson have been appointed to the Remuneration Committee and Steve Crummett will stand down from the Remuneration Committee. Steve Crummett continues as Chairman of the Audit Committee and a member of the Nomination Committee.

Enquiries:

Consort Medical plc

Paul Hayes

01442 867920

Consort Medical plc is a leading one-stop developer and manufacturer of drugs and premium drug delivery devices. We partner with pharmaceutical businesses in providing innovative life improving treatments to patients across the world through two integrated activities:

The design, development and manufacture of high performance medical devices for inhaled, injectable, nasal and ocular drug delivery, as well as point of care diagnostics products.

The development, formulation and manufacture of active pharmaceutical ingredients (APIs) and finished dose drugs to the highest quality standards.

We employ over 2,000 people globally and are committed to investing in patient, clinician and customer driven innovation to create new treatments.

Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE:CSRT) and is organised in two divisions: Bespak and Aesica.

www.consortmedical.com.